This article was originally published in The Gray Sheet
Executive SummaryFirms receive second request for information from the Federal Trade Commission regarding Tyco's proposed acquisition of respiratory products maker Mallinckrodt for about $4.2 bil., announced June 28 (1"The Gray Sheet" July 3, 2000, p. 7). According to Tyco, the request relates specifically to the firms' respective sales of endotracheal tubes, and revenues from that product line amount to "less than $20 mil." The request raises the possibility that the FTC may require Tyco to divest the business before approving the overall deal. The firms still hope to close the deal by September
You may also be interested in...
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced October to November.
The French drugmaker is paying $2.5bn to get hold of THOR-707 which it claims has the potential to become the best-in-class IL-2 therapeutic for solid tumors, thanks to improved pharmacology and less frequent dosing.